Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
Veea and Totalplay Advance Commercial Plans for Secure, AI-Powered Business Services in Mexico
Building An AM Quality Data Backbone That Makes AI Credible
Visionstate Announces $750,000 financing to Support International Expansion and Strategic Growth
Local AI Registry Launches First Public Registry of AI Business Recommendations
Agereh Technologies to Attend 2026 ACI-NA Annual Conference & Exhibition in Philadelphia